Alfredo Carrato

Alfredo Carrato publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alfredo Carrato sits on this spectrum.

Alfredo Carrato D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alfredo Carrato sits on this spectrum.

Overview

Best Publications

• Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

  Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt

  1621
  Citations

• NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

  Montserrat García-Closas;Núria Malats;Debra Silverman;Mustafa Dosemeci

  764
  Citations

• Bladder Cancer and Exposure to Water Disinfection By-Products through Ingestion, Bathing, Showering, and Swimming in Pools

  Cristina M. Villanueva;Kenneth P. Cantor;Joan O. Grimalt;Nuria Malats

  749
  Citations

• Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

  Felipe Cardenal;M. Paz López-Cabrerizo;Antonio Antón;Vicente Alberola

  584
  Citations

• A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

  Nathaniel Rothman;Montserrat Garcia-Closas;Nilanjan Chatterjee;Nuria Malats

  499
  Citations

• Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium

  Michael Goggins;Kasper Alexander Overbeek;Randall Brand;Sapna Syngal

  481
  Citations

• Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas

  Silvia Hernández;Elena López-Knowles;Josep Lloreta;Manolis Kogevinas

  381
  Citations

• Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group

  Bernard Nordlinger;Eric Van Cutsem;Philippe Rougier;Claus Henning Köhne

  366
  Citations

• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology

  Angela N. Bartley;Mary Kay Washington;Carol Colasacco;Christina B. Ventura

  360
  Citations

• Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

  Eduardo Díaz-Rubio;Jose Tabernero;Auxiliadora Gómez-España;Bartomeu Massutí

  357
  Citations

• Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage

  Miquel Porta;Xavier Fabregat;Núria Malats;Luisa Guarner

  348
  Citations

• Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers

  Hans Vasen;Isaura Ibrahim;Carmen Guillen Ponce;Emily P. Slater

  334
  Citations

• Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.

  Cristina Balbás-Martínez;Ana Sagrera;Enrique Carrillo-de-Santa-Pau;Julie Earl

  316
  Citations

• Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

  Yves Allory;Willemien Beukers;Ana Sagrera;Marta Flández

  312
  Citations

• Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case–control study

  Lee E Moore;Ruth M Pfeiffer;Cristina Poscablo;Francisco X Real

  289
  Citations

• Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.

  V. Alberola;C. Camps;M. Provencio;D. Isla

  285
  Citations

• A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs

  A Carrato;A Falcone;M Ducreux;Juan W Valle

  281
  Citations

• PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

  Elena López-Knowles;Silvia Hernández;Núria Malats;Manolis Kogevinas

  261
  Citations

• Polymorphisms in GSTT1, GSTZ1, AND CYP2E1, disinfection by-products, and risk of bladder cancer in Spain

  Kenneth P. Cantor;Cristina M. Villanueva;Debra T. Silverman;Jonine D. Figueroa

  260
  Citations

• Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer

  Miquel Porta;Núria Malats;Manuel Jariod;Joan O Grimalt

  257
  Citations